InMed Pharmaceuticals Reports Amendment to Mentari Financing Agreement

What Happened InMed Pharmaceuticals (INM) filed a Current Report on Form 8-K on July 22, 2026 to disclose that Mentari Therapeutics, Inc. issued a press release announcing entry into Amendment No. 1 to a Securities Purchase Agreement. The press release was furnished as Exhibit 99.1 to the 8-K; the amendment itself is referenced as Exhibit 10.1 (with certain exhibits/schedules omitted pursuant to Item 601(a)(5) of Regulation S‑K).

Key Details

• Date of disclosure and press release: July 22, 2026.
• Document referenced: Amendment No. 1 to the Securities Purchase Agreement, dated July 22, 2026, between Mentari Therapeutics, Inc. and the investors party thereto (listed as Exhibit 10.1).
• Press release: Issued July 22, 2026 and furnished as Exhibit 99.1 to the Form 8-K.
• Omitted materials: Exhibits and/or schedules to the amendment have been omitted under Item 601(a)(5); InMed will furnish omitted exhibits to the SEC upon request and may seek confidential treatment under Rule 24b‑2.

Why It Matters This 8-K is a Regulation FD/Other Events disclosure notifying investors that Mentari (an entity related to InMed’s business interests) has amended a financing agreement. Changes to a securities purchase agreement can affect Mentari’s financing, investor rights, or capitalization. Retail investors should review the furnished press release (Exhibit 99.1) and may request the omitted amendment exhibits from the SEC if they need full contract details.